# Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914

> **NCT00290251** · PHASE2 · COMPLETED · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 72 (actual)

## Conditions studied

- Leiomyoma

## Interventions

- **DRUG:** ulipristal acetate 20 mg
- **DRUG:** ulipristal acetate 10 mg
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00290251
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2009-07
- **Final completion:** 2010-08
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2024-07-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00290251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00290251, "Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00290251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*